2D) induced by HG exposure was also attenuated
Meanwhile, Structure Therapeutics reported positive mid-stage results for its oral GLP-1 agonist aleniglipron in adults with obesity, with plans to initiate a Phase III program by mid-2026 following discussions with the FDA
On the one hand, this should be expected if after losing weight someone stops everything they did to lose weight and returns to doing everything exactly as they did while gaining weight
However, that is both Wegovy 7.2mg and CagriSema (2 assets) that are competitive to Tirzepatide SURMOUNT-1 data as a placebo-adjusted weight loss of -20.1% and likely to be in commercialisation in the US in 2026 and early 2027
Mar 1, 2026 Every vial of compounded semaglutide costs money
We are currently experiencing intermittent supply disruptions on the Ozempic pen that delivers 0.25 mg and 0.5 mg doses due to the combination of incredible demand coupled with overall global supply constraints